For 3Q24, DHT reported $42,400/day fleet-wide TCE and $21,500/day break-even cash flow. TCE fleet rates declined by 13.6% QoQ ...
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback